Deal of the Day — limited-time pharmacy picks!
Twinaqt 50/300mg Tablet

Twinaqt 50/300mg Tablet

Prescription requiredRx Required

Salt Composition: Dolutegravir and lamivudine

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

30 Tablets in Bottle

About The Product

HIV

Description

Twinaqt 50/300mg Tablet is an antiviral medicine with the combination of Dolutegravir and lamivudine as an active ingredients. It is prescribed to manage human immunodeficiency virus (HIV) infection in both adults and children weighing at least 40 kg.

It can be given for patients who are responding well to treatment and have no history of treatment failure, as well as for those beginning antiretroviral medication or to replace an existing treatment. It should be taken with food at the same time each day to get effective results.

Don't take more than the recommended dose.​

Uses

  • Treatment of HIV infection

Side Effects

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.

Some common side effects of Twinaqt 50/300mg Tablet   include:

  • Headache
  • Fatigue
  • Stomach Pain
  • Increased Lipase Enzyme In Blood
  • Loose And Watery Stools
  • Dizziness
  • Nausea

How To Use

  • The dosage and treatment duration of the Twinaqt 50/300mg Tablet are decided by the doctor according overall patient's health.
  • This tablet should be taken with or without food, but at the fix time every day to get effective results. Don't miss a dose or overdose on the medicine.​​

How It Works

  • Twinaqt 50/300mg Tablet is an antiviral medicine with the combination of Tenofovir, Disoproxil Lamivudine and Dolutegravir as an active ingredients.
  • It works by preventing the multiplication of human immunodeficiency virus in human cells to stop the production of new viruses and clears up the infection from the body.

Safety Advice

Alcohol
Avoid the consumption of alcohol while taking Twinaqt 50/300mg Tablet, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms
Pregnancy
Do not take Twinaqt 50/300mg Tablet without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Breast Feeding
Breastfeeding women should discuss the potential risks and benefits of the Twinaqt 50/300mg Tablet with their healthcare provider before starting treatment
Driving
Twinaqt 50/300mg Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.
Kidney
Share your medical history with the doctor before starting the Twinaqt 50/300mg Tablet. Do not take it without consulting a doctor if you have any kidney related issue.
Liver
Share your medical history with the doctor before starting the Twinaqt 50/300mg Tablet. Do not take it without consulting a doctor if you have any liver related issue

FAQs

Twinaqt 50/300mg Tablet is an antiviral medicine that works by blocking the replication of the virus to reduce its levels in the body.

References

  • Cattaneo, D., Capetti, A., & Rizzardini, G. (2019). Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opinion on Drug Metabolism & Toxicology, 15(3), 245-252. https://pubmed.ncbi.nlm.nih.gov/30704313/
  • Ciccullo, A., Borghi, V., Giacomelli, A., Cossu, M. V., Sterrantino, G., Latini, A., ... & Baldin, G. (2021). Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding. JAIDS Journal of Acquired Immune Deficiency Syndromes, 88(3), 234-237. https://pubmed.ncbi.nlm.nih.gov/34446677/
  • Zamora, F. J., Dowers, E., Yasin, F., & Ogbuagu, O. (2019). Dolutegravir and lamivudine combination for the treatment of HIV-1 infection. HIV/AIDS-Research and Palliative Care, 255-263. https://pubmed.ncbi.nlm.nih.gov/31749636/
  • Joly, V., Burdet, C., Landman, R., Vigan, M., Charpentier, C., Katlama, C., ... & Yazdanpanah, Y. (2019). Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). Journal of Antimicrobial Chemotherapy, 74(3), 739-745. https://pubmed.ncbi.nlm.nih.gov/30476165/
  • Patel, R., Evitt, L., Mariolis, I., Di Giambenedetto, S., d’Arminio Monforte, A., Casado, J., ... & Koteff, J. (2021). HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review. Infectious diseases and therapy, 10(4), 2051-2070.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026